Epstein Secrets

ust 25, 2016 at 9:35:43 AM EDT To: Richard Kahn Rich, With yesterday's weakness in healthcare on pric

this for your attention. Our view is that there is good risk-reward for TEVA going into a patent decision expected tomorrow relating to its key drug Copaxone Copaxone US is - 16% of sales, ^21% globally)). If the decision is unfavorable, we would likely look to add on any weakness. Our analyst is already building in

ust 25, 2016 at 9:35:43 AM EDT To: Richard Kahn Rich, With yesterday's weakness in healthcare on pric

this for your attention. Our view is that there is good risk-reward for TEVA going into a patent decision expected tomorrow relating to its key drug Copaxone Copaxone US is —16% of sales, —21% globally)). If the decision is unfavorable, we would likely look to add on any weakness. Our analyst is already building in c

25, 2016 at 9:35:43 AM EDT To: Richard Kahn c > Rich, With yesterday's weakness in healthcare on pric

this for your attention. Our view is that there is good risk-reward for TEVA going into a patent decision expected tomorrow relating to its key drug Copaxone Copaxone US is —16% of sales, —21% globally)). If the decision is unfavorable, we would likely look to add on any weakness. Our analyst is already building in